A colleague is managing a 69 yo woman s/p heart transplant (transplant 2001 for non-ischemic cardiomyopathy) diagnosed with CP CML. She could not tolerate imatinib, switched to dasatinib and then bosutinib. Unfortunately, very severe PAH discovered after 3 years of dasatinib shortly after starting BOS at 200 mg. Reason for switch from DAS to BOS in early 2020 was pleural effusion and shortness of breath. The only echo in 2018 while on DAS did not comment on PASP being elevated. The next echo was after another year of DAS and 6 mo of BOS – PASP was 57 mm Hg. I believe DAS was the prime driver here (very rare in HT pts) but case reports of BOS suggest it can worsen it and this could have occurred. Hard to say honestly in this particular case given timing.
Generally, it could be cross class due to other kinase targeting. Pharmacovigilance paper implicating them all (except imatinib, nilotinib is less associated but still associated):
erj.ersjournals.com/content/erj/early/20....02472-2018.full.pdf
I’ve always wanted to blame SRC kinase inhibition primarily – although this is too simplistic. Bosutinib and dasatinib are both dual Src/Abl inhibitors – but clearly given the difference in incidence of PAH between the two drugs – that can’t be the whole story. VEGF targeting (and some SRC) with ponatinib could be problematic as well.
Asciminib may be a reasonable next step given its narrow profile. Are there any concerns with Asciminib that may not be published? It may be hard to get Novartis to agree to compassionate use…. Yes PASPs are slowly declining off therapy. She has DM,2 and hyperlipidemia, CKD and is 69. Wish we could use IM but the patient does not like it even at 200 to 300 mg due to fluid retention (yes I will revisit this with her primary oncologist). That said, however she did respond to it previously achieving BCR-ABL of 0.13%. Seems to me the safest choice but one that may not be acceptable.
Your thoughts will be much appreciated.